Pub Date : 2018-03-03DOI: 10.14302/ISSN.2642-9241.JRD-18-1958
T. Taba, H. DongKhac, Q. Do, B. DaoNgoc, L. NguyễnHuy, N. NguyenViet
Methods: We performed a prospective, nonrandomized, single center longitudinal study in 30 stable COPD patients with heterogeneous severe emphysema on CT-scanner, the average age of 65.17 years old, FEV1≤35 %pred., TLC ≥ 100 %pred., RV ≥ 150 %pred. and 6MWT < 450 meters. The Zephyr one-way bronchial valves (PulmonX, Redwood City, CA, USA) with the size of 5.5 mm and 4mm were placed in lobar or segmental bronchi via flexible bronchoscopy. 28 patients were placed only one valve, 1 patient with two and 1 patient with three valves. 23 valves with the size 5.5 mm diameters and 10 valves with the size 4.0mm used. All patients received optimal medical treatment at the time of procedure and during the study period. Outcomes will be assessed at 3 months after treatment include the changes of clinic, and lung function, the occurrence of complications.
方法:采用前瞻性、非随机、单中心纵向研究，对30例稳定型COPD合并异质性严重肺气肿患者进行ct扫描，平均年龄65.17岁，平均FEV1≤35%。， TLC≥100%;， RV≥150%。6MWT < 450米。通过柔性支气管镜将尺寸分别为5.5 mm和4mm的Zephyr单向支气管瓣(PulmonX, Redwood City, CA, USA)置入大叶支气管或节段支气管。仅放置一个瓣膜28例，放置两个瓣膜1例，放置三个瓣膜1例。直径5.5 mm的阀门23个，直径4.0mm的阀门10个。所有患者在手术时和研究期间都得到了最佳的治疗。治疗后3个月评估临床变化、肺功能、并发症发生情况。
{"title":"Results of Bronchoscopic Lung Volume Reduction With One-way Valve in Patients With Severe Emphysema in Vietnam","authors":"T. Taba, H. DongKhac, Q. Do, B. DaoNgoc, L. NguyễnHuy, N. NguyenViet","doi":"10.14302/ISSN.2642-9241.JRD-18-1958","DOIUrl":"https://doi.org/10.14302/ISSN.2642-9241.JRD-18-1958","url":null,"abstract":"Methods: We performed a prospective, nonrandomized, single center longitudinal study in 30 stable COPD patients with heterogeneous severe emphysema on CT-scanner, the average age of 65.17 years old, FEV1≤35 %pred., TLC ≥ 100 %pred., RV ≥ 150 %pred. and 6MWT < 450 meters. The Zephyr one-way bronchial valves (PulmonX, Redwood City, CA, USA) with the size of 5.5 mm and 4mm were placed in lobar or segmental bronchi via flexible bronchoscopy. 28 patients were placed only one valve, 1 patient with two and 1 patient with three valves. 23 valves with the size 5.5 mm diameters and 10 valves with the size 4.0mm used. All patients received optimal medical treatment at the time of procedure and during the study period. Outcomes will be assessed at 3 months after treatment include the changes of clinic, and lung function, the occurrence of complications.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"1 1","pages":"08"},"PeriodicalIF":0.0,"publicationDate":"2018-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45578915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Akamatsu, T. Shirai, Yuko Tanaka, Hirofumi Watanabe, Y. Endo, Y. Shimoda, Takahito Suzuki, Rie Noguchi, M. Saigusa, A. Yamamoto, Y. Shishido, T. Akita, S. Morita, K. Asada
Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and 17 patients completed the study (mean age: 73 years and GOLD I/II/III/IV, 5/10/1/1). The mean CAT scores significantly improved (9.2 to 5.4, p = 0.015) and 10 patients (58.8%) showed ≥2 points improvement, a minimal clinically important difference. The mean FeNO levels significantly decreased from 63.0 to 34.3 ppb (p < 0.006). However, there were no changes in mMRC scores, spirometric indices, or forced oscillation parameters. Conclusions: FeNO-guided treatment with BUD/FM improves symptoms in patients with ACO.
{"title":"Usefulness of Fractional Exhaled Nitric Oxide-Guided Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap","authors":"T. Akamatsu, T. Shirai, Yuko Tanaka, Hirofumi Watanabe, Y. Endo, Y. Shimoda, Takahito Suzuki, Rie Noguchi, M. Saigusa, A. Yamamoto, Y. Shishido, T. Akita, S. Morita, K. Asada","doi":"10.4236/OJRD.2018.81001","DOIUrl":"https://doi.org/10.4236/OJRD.2018.81001","url":null,"abstract":"Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and 17 patients completed the study (mean age: 73 years and GOLD I/II/III/IV, 5/10/1/1). The mean CAT scores significantly improved (9.2 to 5.4, p = 0.015) and 10 patients (58.8%) showed ≥2 points improvement, a minimal clinically important difference. The mean FeNO levels significantly decreased from 63.0 to 34.3 ppb (p < 0.006). However, there were no changes in mMRC scores, spirometric indices, or forced oscillation parameters. Conclusions: FeNO-guided treatment with BUD/FM improves symptoms in patients with ACO.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"08 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2018-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43116602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mats Clarsund, Marcus Fornbacke, L. Uller, S. Johnston, C. A. Emanuelsson
Common colds incur significant costs in terms of sick leave and personal discomfort for affected individuals. This study investigated the performance of ColdZyme® Mouth Spray (ColdZyme), a protective barrier against common cold, in rhinovirus-inoculated healthy volunteers. This randomized, doubleblind, placebo-controlled pilot study was conducted on 46 healthy volunteers inoculated with rhinovirus 16 via the nose. Subjects self-administered ColdZyme or placebo 6 times daily for 11 days. Symptoms were recorded daily in a diary. Rhinovirus 16 in nasal and oropharyngeal samples at days 0, 3, 4, 6, 7 and 10 were quantified by RT-qPCR. The primary outcome measure was the reduction in viral load in oropharyngeal samples. Rhinovirus 16 was only detected in 35 out of 46 inoculated subjects. Exploratory analysis measuring the total viral load (i.e., area under the curve (AUC)) for days 3 - 10 in successfully inoculated subjects found that ColdZyme treatment resulted in a lower total viral load in the oropharynx (p = 0.023). In subjects who experienced symptomatic common cold, irrespectively, if virus were detected, treatment with ColdZyme resulted in a reduction in the number of days with common cold symptoms from 6.5 to 3.0 days (p = 0.014) in comparison to placebo. ColdZyme reduced virus infection in the oropharynx and reduced the number of days with common cold symptoms and highlights the possible importance of the oropharynx in common cold infections. Suitable outcome measures for a feasible study on ColdZyme are total viral load in the oropharynx in subjects having detectable virus present in nasal or oropharyngeal samples.
{"title":"A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold","authors":"Mats Clarsund, Marcus Fornbacke, L. Uller, S. Johnston, C. A. Emanuelsson","doi":"10.4236/OJRD.2017.74013","DOIUrl":"https://doi.org/10.4236/OJRD.2017.74013","url":null,"abstract":"Common colds incur significant costs in terms of sick leave and personal discomfort for affected individuals. This study investigated the performance of ColdZyme® Mouth Spray (ColdZyme), a protective barrier against common cold, in rhinovirus-inoculated healthy volunteers. This randomized, doubleblind, placebo-controlled pilot study was conducted on 46 healthy volunteers inoculated with rhinovirus 16 via the nose. Subjects self-administered ColdZyme or placebo 6 times daily for 11 days. Symptoms were recorded daily in a diary. Rhinovirus 16 in nasal and oropharyngeal samples at days 0, 3, 4, 6, 7 and 10 were quantified by RT-qPCR. The primary outcome measure was the reduction in viral load in oropharyngeal samples. Rhinovirus 16 was only detected in 35 out of 46 inoculated subjects. Exploratory analysis measuring the total viral load (i.e., area under the curve (AUC)) for days 3 - 10 in successfully inoculated subjects found that ColdZyme treatment resulted in a lower total viral load in the oropharynx (p = 0.023). In subjects who experienced symptomatic common cold, irrespectively, if virus were detected, treatment with ColdZyme resulted in a reduction in the number of days with common cold symptoms from 6.5 to 3.0 days (p = 0.014) in comparison to placebo. ColdZyme reduced virus infection in the oropharynx and reduced the number of days with common cold symptoms and highlights the possible importance of the oropharynx in common cold infections. Suitable outcome measures for a feasible study on ColdZyme are total viral load in the oropharynx in subjects having detectable virus present in nasal or oropharyngeal samples.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"7 1","pages":"125-135"},"PeriodicalIF":0.0,"publicationDate":"2017-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46790516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Agustin, Hong-yan Chang, J. Unterborn, A. Andoh-Duku
Background: Dyspnea in obesity is common and dyspnea questionnaires are mostly validated for chronic respiratory diseases. The study aims to assess how modified Medical Research Council (mMRC) dyspnea scale correlates with post exercise dyspnea Borg scale in 6-minute walk test of the obese population. Methods: We performed a retrospective observational study on 342 obese patients with 6 MWT tests from February 2008 to November 2014 at a single tertiary hospital. Linear regression analysis was used to assess the relationship between mMRC and Borg dyspnea score. Fractional polynomial regression was used to analyze the relationship of mMRC and Borg scores with BMI. Results: MMRC dyspnea score was a strong predictor of post exercise dyspnea Borg score in the obese population in a univariate regression model (coefficient = 0.764, p ≤ 0.001). When adjusted to age, BMI, 6 MWT distance and PFT parameters in a multivariate regression model, the relationship remained statistically significant (coefficient = 0.587, p ≤ 0.001). The relationship was stronger in obese group with no airflow obstruction. Conclusion: In obese population, pre-exercise mMRC dyspnea score correlates significantly with post exercise dyspnea Borg score regardless of airflow obstruction. This is the first validity study regarding mMRC scale in assessing dyspnea in the obese population.
{"title":"Correlation of Self-Reported Breathlessness with Post Exercise Dyspnea in Obesity","authors":"M. Agustin, Hong-yan Chang, J. Unterborn, A. Andoh-Duku","doi":"10.4236/OJRD.2017.74015","DOIUrl":"https://doi.org/10.4236/OJRD.2017.74015","url":null,"abstract":"Background: Dyspnea in obesity is common and dyspnea questionnaires are mostly validated for chronic respiratory diseases. The study aims to assess how modified Medical Research Council (mMRC) dyspnea scale correlates with post exercise dyspnea Borg scale in 6-minute walk test of the obese population. Methods: We performed a retrospective observational study on 342 obese patients with 6 MWT tests from February 2008 to November 2014 at a single tertiary hospital. Linear regression analysis was used to assess the relationship between mMRC and Borg dyspnea score. Fractional polynomial regression was used to analyze the relationship of mMRC and Borg scores with BMI. Results: MMRC dyspnea score was a strong predictor of post exercise dyspnea Borg score in the obese population in a univariate regression model (coefficient = 0.764, p ≤ 0.001). When adjusted to age, BMI, 6 MWT distance and PFT parameters in a multivariate regression model, the relationship remained statistically significant (coefficient = 0.587, p ≤ 0.001). The relationship was stronger in obese group with no airflow obstruction. Conclusion: In obese population, pre-exercise mMRC dyspnea score correlates significantly with post exercise dyspnea Borg score regardless of airflow obstruction. This is the first validity study regarding mMRC scale in assessing dyspnea in the obese population.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"07 1","pages":"141-149"},"PeriodicalIF":0.0,"publicationDate":"2017-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43983856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The common cold is one of the most frequently encountered infectious diseases in humans and, despite the modest severity in most cases; it presents a significant economic burden upon society and individuals. ColdZyme® Mouth Spray (ColdZyme®, Enzymatica AB, Lund, Sweden) is a mouth spray intended to reduce the probability of catching a cold and can also help shorten the duration of a cold if used at an early stage of the infection, by forming a barrier on the oropharyngeal mucous membrane. This study evaluated the effect of ColdZyme® on common cold related sick-leave in preschool (kindergarten) staff. Fifteen preschool staff members were evaluated over a 6-month period and ColdZyme® was used according to instructions. Sick-leave days were recorded and compared to historical data. The number of average sick leave days decreased during the period from 7.4 days to 4.1 days (p = 0.04). It is notable that, if occurring, the majority of subjects perceived a common cold infection as milder than usual. Conclusion: Using ColdZyme® to apply a barrier to the pharyngeal mucous membrane may be an easy and practical way to prevent or reduce infections and corresponding sick leave in personnel from the preschool environment.
{"title":"Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool Staff","authors":"Mats Clarsund","doi":"10.4236/OJRD.2017.74014","DOIUrl":"https://doi.org/10.4236/OJRD.2017.74014","url":null,"abstract":"The common cold is one of the most frequently encountered infectious diseases in humans and, despite the modest severity in most cases; it presents a significant economic burden upon society and individuals. ColdZyme® Mouth Spray (ColdZyme®, Enzymatica AB, Lund, Sweden) is a mouth spray intended to reduce the probability of catching a cold and can also help shorten the duration of a cold if used at an early stage of the infection, by forming a barrier on the oropharyngeal mucous membrane. This study evaluated the effect of ColdZyme® on common cold related sick-leave in preschool (kindergarten) staff. Fifteen preschool staff members were evaluated over a 6-month period and ColdZyme® was used according to instructions. Sick-leave days were recorded and compared to historical data. The number of average sick leave days decreased during the period from 7.4 days to 4.1 days (p = 0.04). It is notable that, if occurring, the majority of subjects perceived a common cold infection as milder than usual. Conclusion: Using ColdZyme® to apply a barrier to the pharyngeal mucous membrane may be an easy and practical way to prevent or reduce infections and corresponding sick leave in personnel from the preschool environment.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"07 1","pages":"136-140"},"PeriodicalIF":0.0,"publicationDate":"2017-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45349369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-28DOI: 10.14302/ISSN.2642-9241.JRD-17-1683
Hu Jieying, Zheng Ze-guang, Yang Feng, Zhong Lihong, Chen Rongchang
Objective: Investigate the effect of connecting a waterproof device at the front end of the piezometric tube on pressure transmission and patient-machine synchronization during the noninvasive ventilation. Method: In test 1, the waterproof device was connected to the piezometric tube and put into a closed container, the pressure inside the container was varied to observe the corresponding pressure change in the piezometric tube. In test 2, a waterproof device was connected in front of the piezometric tube during noninvasive ventilation.12 subjects were received noninvasive ventilator so that dynamic changes of the pressure inside the mask (Pmask) and piezometric tube (Ptube) could be measured. Results: In test 1, when the pressure in the container was gradually increased to 50 cmH2O and then decreased to 0, the pressure inside the piezometric tube changed synchronously with the pressure inside the container, with no statistically significant difference between the pressures (0.009 ± 0.138) cmH2O. In test 2, there was no significant increase in triggering time, pressure, and power after connecting the waterproof device at the front end of the piezometric tube. There was no significant difference in the platform pressure and baseline pressure as measured by Pmask, before and after connecting the waterproof device. Finally, there was no significant difference in the platform pressure and baseline pressure between Pmask and Ptube after connecting the waterproof device. Conclusion: Connecting the waterproof device at the front end of the piezometric tube can prevent condensate from entering the tube without affecting pressure transmission . DOI : COMING SOON Corresponding author: Zheng Zeguang , First Affiliated Hospital of Guangzhou Medical University (State Key Laboratory of Respiratory Disease), Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong 510120, China
{"title":"Effect of A Waterproof Device in the Noninvasive Ventilation Circuit On Patient-machine Synchronization","authors":"Hu Jieying, Zheng Ze-guang, Yang Feng, Zhong Lihong, Chen Rongchang","doi":"10.14302/ISSN.2642-9241.JRD-17-1683","DOIUrl":"https://doi.org/10.14302/ISSN.2642-9241.JRD-17-1683","url":null,"abstract":"Objective: Investigate the effect of connecting a waterproof device at the front end of the piezometric tube on pressure transmission and patient-machine synchronization during the noninvasive ventilation. Method: In test 1, the waterproof device was connected to the piezometric tube and put into a closed container, the pressure inside the container was varied to observe the corresponding pressure change in the piezometric tube. In test 2, a waterproof device was connected in front of the piezometric tube during noninvasive ventilation.12 subjects were received noninvasive ventilator so that dynamic changes of the pressure inside the mask (Pmask) and piezometric tube (Ptube) could be measured. Results: In test 1, when the pressure in the container was gradually increased to 50 cmH2O and then decreased to 0, the pressure inside the piezometric tube changed synchronously with the pressure inside the container, with no statistically significant difference between the pressures (0.009 ± 0.138) cmH2O. In test 2, there was no significant increase in triggering time, pressure, and power after connecting the waterproof device at the front end of the piezometric tube. There was no significant difference in the platform pressure and baseline pressure as measured by Pmask, before and after connecting the waterproof device. Finally, there was no significant difference in the platform pressure and baseline pressure between Pmask and Ptube after connecting the waterproof device. Conclusion: Connecting the waterproof device at the front end of the piezometric tube can prevent condensate from entering the tube without affecting pressure transmission . DOI : COMING SOON Corresponding author: Zheng Zeguang , First Affiliated Hospital of Guangzhou Medical University (State Key Laboratory of Respiratory Disease), Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong 510120, China","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"1 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46792589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study evaluated the protective effect of ColdZyme on common cold infections in elite athletes from three different sports (biathlon, ice-hockey and handball), and assessed the level of reduction in corresponding sick days. The biathlon team (n = 11) and the ice-hockey team (n = 29) significantly reduced the average number of sick days by 51% respectively 67% compared to historical data. No historical data on sick days was available for the handball team but 76% of those who experiences a cold during the study period reported little or very little impact on training and competition. Conclusion: Using ColdZyme may be an easy and practical way for elite athletes to protect themselves against the common cold and to prevent corresponding unwanted absence from training and competition.
{"title":"Evaluation of ColdZyme Mouth Spray for the Protection against Common Cold in Elite Athletes to Reduce Unwanted Absence from Training and Competition","authors":"Mats Clarsund","doi":"10.4236/OJRD.2017.73010","DOIUrl":"https://doi.org/10.4236/OJRD.2017.73010","url":null,"abstract":"This study evaluated the protective effect of ColdZyme on common cold infections in elite athletes from three different sports (biathlon, ice-hockey and handball), and assessed the level of reduction in corresponding sick days. The biathlon team (n = 11) and the ice-hockey team (n = 29) significantly reduced the average number of sick days by 51% respectively 67% compared to historical data. No historical data on sick days was available for the handball team but 76% of those who experiences a cold during the study period reported little or very little impact on training and competition. Conclusion: Using ColdZyme may be an easy and practical way for elite athletes to protect themselves against the common cold and to prevent corresponding unwanted absence from training and competition.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"07 1","pages":"103-109"},"PeriodicalIF":0.0,"publicationDate":"2017-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44888328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Uda, S. Shiotsu, Ayaka Omura, Ryosuke Hamashima, A. Yoshimura, Naoko Kurisu, T. Sagawa, Koichi Hasegawa, T. Yuba, Chieko Takumi, Seiko Ono, Noriya Hiraoka
Human T lymphotropic virus type 1 (HTLV-1) is endemic in the southern part of Japan. Infection of the virus can cause adult T cell leukemia/lymphoma (ATL), while most infected individuals remain in a carrier state for a long period of time. Although rare cases of carriers, like ATL patients, who developed opportunistic infections, have been reported, hematological changes of carriers who are prone to opportunistic infections have not been well defined. Here, we present a case of an HTLV-1 carrier who developed Mycobacterium intracellulare infection and Pneumocystis jirovecii pneumonia (PcP) simultaneously. Flow cytometric analysis of bone marrow cells revealed an aberrant compositional change similar to that in ATL patients. This suggests the presence of a pre-ATL state prior to the development of ATL, which is notable in terms of underlying cellular immunodeficiency.
{"title":"A Human T Lymphotropic Virus Type 1 Carrier Coinfected with Mycobacterium intracellulare and Pneumocystis jirovecii with a Characteristic Compositional Change of Bone Marrow Cells","authors":"S. Uda, S. Shiotsu, Ayaka Omura, Ryosuke Hamashima, A. Yoshimura, Naoko Kurisu, T. Sagawa, Koichi Hasegawa, T. Yuba, Chieko Takumi, Seiko Ono, Noriya Hiraoka","doi":"10.4236/OJRD.2017.73011","DOIUrl":"https://doi.org/10.4236/OJRD.2017.73011","url":null,"abstract":"Human T lymphotropic virus type 1 (HTLV-1) is endemic in the southern part of Japan. Infection of the virus can cause adult T cell leukemia/lymphoma (ATL), while most infected individuals remain in a carrier state for a long period of time. Although rare cases of carriers, like ATL patients, who developed opportunistic infections, have been reported, hematological changes of carriers who are prone to opportunistic infections have not been well defined. Here, we present a case of an HTLV-1 carrier who developed Mycobacterium intracellulare infection and Pneumocystis jirovecii pneumonia (PcP) simultaneously. Flow cytometric analysis of bone marrow cells revealed an aberrant compositional change similar to that in ATL patients. This suggests the presence of a pre-ATL state prior to the development of ATL, which is notable in terms of underlying cellular immunodeficiency.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"07 1","pages":"110-116"},"PeriodicalIF":0.0,"publicationDate":"2017-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41532924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Grigorakos, G. Poulakou, D. Lazarescu, P. Myrianthefs, N. Markou, Maria Bikou, A. Petineli, K. Kokkinis
We report the case of a patient with pulmonary fibrosis, developed as an adverse reaction to nitrofurantoin therapy received for totally 6 months for the prevention of recurrent urinary tract infections. Chest X-ray and CT scan revealed extensive elements of interstitial pulmonary fibrosis. After diagnosis, administration of nitrofurantoin was immediately stopped; and specific prolonged therapy with low-dose corticosteroids per os and inhaled steroids were administered. The patient responded successfully both clinically and biochemically and possible digestive system side effects were prevented through the administration of gastroprotection medication. For the prevention of urinary tract infection, the patient received well tolerated therapy with fosfomycin which was further continued as a prophylactic agent.
{"title":"Pulmonary Fibrosis Due to Nitrofurantoin Therapy: A Case Report","authors":"L. Grigorakos, G. Poulakou, D. Lazarescu, P. Myrianthefs, N. Markou, Maria Bikou, A. Petineli, K. Kokkinis","doi":"10.4236/OJRD.2017.73012","DOIUrl":"https://doi.org/10.4236/OJRD.2017.73012","url":null,"abstract":"We report the case of a patient with pulmonary fibrosis, developed as an adverse reaction to nitrofurantoin therapy received for totally 6 months for the prevention of recurrent urinary tract infections. Chest X-ray and CT scan revealed extensive elements of interstitial pulmonary fibrosis. After diagnosis, administration of nitrofurantoin was immediately stopped; and specific prolonged therapy with low-dose corticosteroids per os and inhaled steroids were administered. The patient responded successfully both clinically and biochemically and possible digestive system side effects were prevented through the administration of gastroprotection medication. For the prevention of urinary tract infection, the patient received well tolerated therapy with fosfomycin which was further continued as a prophylactic agent.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"07 1","pages":"117-124"},"PeriodicalIF":0.0,"publicationDate":"2017-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48380530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Montgomery, Allen Luk, A. Johnson, J. Vossoughi
Research reports on pulmonary function measurements often mention caffeine abstinence as a condition for testing subjects. Yet, the effects of caffeine on respiration are not well documented. This study was intended to investigate the physiological effects of caffeine on respiratory resistance measurements and the necessity of caffeine avoidance in such testing. Thirty-one subjects were administered caffeine in pill form for dosages in the range of 3 - 4.5 mg/kg body weight. Respiratory resistance was measured with the Airflow Perturbation Device every 15 minutes after caffeine ingestion until a full hour of elapsed time. No changes were noted in inhalation, exhalation, and average respiratory resistances during the times of measurements. The conclusion is that for low dosages of caffeine, respiratory resistance measurements are not affected by caffeine ingestion prior to testing.
{"title":"Testing Low Doses of Caffeine on Respiratory Resistance Using the Airflow Perturbation Device","authors":"M. Montgomery, Allen Luk, A. Johnson, J. Vossoughi","doi":"10.4236/OJRD.2017.72006","DOIUrl":"https://doi.org/10.4236/OJRD.2017.72006","url":null,"abstract":"Research reports on pulmonary function measurements often mention caffeine abstinence as a condition for testing subjects. Yet, the effects of caffeine on respiration are not well documented. This study was intended to investigate the physiological effects of caffeine on respiratory resistance measurements and the necessity of caffeine avoidance in such testing. Thirty-one subjects were administered caffeine in pill form for dosages in the range of 3 - 4.5 mg/kg body weight. Respiratory resistance was measured with the Airflow Perturbation Device every 15 minutes after caffeine ingestion until a full hour of elapsed time. No changes were noted in inhalation, exhalation, and average respiratory resistances during the times of measurements. The conclusion is that for low dosages of caffeine, respiratory resistance measurements are not affected by caffeine ingestion prior to testing.","PeriodicalId":83134,"journal":{"name":"The Journal of respiratory diseases","volume":"07 1","pages":"53-61"},"PeriodicalIF":0.0,"publicationDate":"2017-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44250866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：